Nasdaq gnlx.

May 25, 2023 · WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ... Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.WebMay 15, 2023 · WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ... Genelux Corporation Common Stock (GNLX) Real-Time Quotes | Nasdaq Real-Time: GNLX Edit my quotes Genelux Corporation Common Stock (GNLX) 0 Add to Portfolio GNLX GNLX REAL TIME GNLX...

12.06.2023 г. ... 103426 GNLX GENELUX CORP NASDAQ Capital 6.00 2,500,000 1/26/2023 $15,000,000 Priced 3 1241592-105143 QSG QuantaSing Group Ltd NASDAQ Global ...WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug ...

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...WebWESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...WebGenelux Corporation (Nasdaq: GNLX), a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from ...WebFind the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.Web4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ...

We explain how to buy Genelux Corporation Common Stock stock, compare the best stock trading platforms and use a detailed analysis to learn about (GNLX).

Shares of Genelux Corporation (NASDAQ:GNLX) got a boost, shooting 24% to $36.67. Sea Limited (NYSE:SE) shares were also up, gaining 16% to $76.09 after the company reported better-than-expected Q4 ...

WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on ...29. 3. 2023 ... is redefining immuno-oncology. $GNLX is a late clinical-stage biotechnology company focused on improving the lives of patients affected by ...4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ...Dec 1, 2023 · If you're new to stock investing, here's how to buy Genelux stock. What is the 52 week high and low for Genelux (NASDAQ: GNLX)? (NASDAQ: GNLX) Genelux's 52-week high was $40.98, and its 52-week low was $5.35. It is currently -57.93% from its 52-week high and 222.24% from its 52-week low.

Genelux Corporation's (NASDAQ:GNLX) value has fallen 16% in the last week, but insiders who sold US$11m worth of stock over the last year have had less success. Insiders might have been better off holding onto their shares, given that the average selling price of US$23.49 is still below the current share price.Find the latest news headlines from Genelux Corporation Common Stock (GNLX) at Nasdaq.com.NVIDIA Corporation Common Stock. $435.70 -0.93 -0.21%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ... NASDAQ does not use this value to determine compliance with the listing requirements. Inpixon Common Stock (INPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global ...WebMar 23, 2023 · Genelux Corporation. WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical ...

WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...

CIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer. With its cutting-edge technology platform, strong ...WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WebWESTLAKE VILLAGE, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second ...Genelux press release (NASDAQ:GNLX): Q3 GAAP EPS of -$0.20 misses by $0.02. $29.9 million in cash and equivalents. Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage ...Nov 14, 2023 · WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ... Genelux ( NASDAQ: GNLX) is a recently IPO-ed phase 3 stage cancer therapeutics company. Its business is designing “oncolytic viral immunotherapies that are designed to generate a personalized ...Web

52 Week Range 5.35 - 40.98. Market Cap $622.89M. Shares Outstanding 26.18M. Public Float 18.26M. Beta 1.10. Rev. per Employee $749.20K. P/E Ratio N/A. EPS -$0.58. Yield N/A.

FN Media Group Presents USA News Group News Commentary . Vancouver, BC – October 11, 2023 – USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer …

View live Genelux Corporation chart to track its stock's price action. Find market predictions, GNLX financials and market news.Genelux Corporation Common Stock (GNLX) Nasdaq Listed; Nasdaq 100; Data is currently not available. Bid: Ask: Volume: 0. ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...WebGenelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […]May 15, 2023 · Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ... The public float for GNLX is 19.35M, and currently, shorts hold a 4.47% of that float. The average trading volume for GNLX on November 20, 2023 was 226.90K shares. GNLX) stock’s latest price update. The stock price of Genelux Corp (NASDAQ: GNLX) has dropped by -9.53 compared to previous close of 13.12.So far, 2023 has been a great year for Genelux Corporation (NASDAQ:GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that’s primarily ...WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ...WebNov 27, 2023 · The latest price target for Genelux ( NASDAQ: GNLX) was reported by Maxim Group on Tuesday, September 12, 2023. The analyst firm set a price target for 40.00 expecting GNLX to rise to within 12 ... A look at the shareholders of Genelux Corporation (NASDAQ:GNLX) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 57% ownership.Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. As of November 1, 2023, the average one-year price target for ...

Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of.Stock Quote & Chart. NASDAQ: GNLX. $11.90. Nov 30, 2023 4:00 PM EST. Change. +0.2 (+1.71%). Volume. 86,169. Today's Open. $11.79. Previous Close. $11.70.Genelux Co. ( NASDAQ:GNLX – Free Report) – Analysts at HC Wainwright issued their FY2023 earnings per share (EPS) estimates for shares of Genelux in a report released on Monday, November 27th ...WebInstagram:https://instagram. recession resistant stocksfirst trade reviewotcmkts sgtmfast graphs review About. Genelux Corporation, a Delaware · Highlight. A company researching a leading · Exchange. NASDAQ. Listing Date · NASDAQ. Listing Date. 01/26/2023.So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily been active in studies pertaining to ovarian cancer. However, Genelux has also been forthcoming about its V2ACT Immunotherapy, which incorporates … stock market winners and losersindependence financial advisors Shares of Genelux Corporation (NASDAQ:GNLX) got a boost, shooting 24% to $36.67. Sea Limited (NYSE:SE) shares were also up, gaining 16% to $76.09 after the company reported better-than-expected Q4 ...lowest stock price was $5.35 and its highest was $40.98 in the past 12 months. What is Genelux Corp.'s market cap? great llc names Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com. Nasdaq 14,095.21 -8.62(-0.06%) Russell 2000 1,775.06 -26.16(-1.45%) Crude Oil 72.88 -3.78(-4.93%) Gold 1,987.00 +22.70(+1.16%) Genelux Corporation (GNLX) NasdaqCM - NasdaqCM Real Time Price....Genelux Corporation Common Stock (GNLX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.